Analyst Research Report Snapshot

Title:

Surgical Specialties Corporation, Inc.

Price:

$175.00

Provider:

MarketLine (a Datamonitor Company)

Date:

08 Apr 2014

Pages:

40

Type:

AcrobatPDF

Companies referenced:

ANPMF.PK

Available for Immediate Download
Summary:

Surgical Specialties Corporation, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company. Features: - Detailed information on Surgical Specialties Corporation, Inc. required for business and competitor intelligence needs - A study of the major internal and external factors affecting Surgical Specialties Corporation, Inc. in the form of a SWOT analysis - An in-depth view of the business model of Surgical Specialties Corporation, Inc. including a breakdown and examination of key business segments - Intelligence on Surgical Specialties Corporation, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors - News about Surgical Specialties Corporation, Inc., such as business expansion, restructuring, and contract wins - Large number of easy-to-grasp charts and graphs that present important data and key trends Highlights: Surgical Specialties Corporation (Surgical Specialties or ‘the company), formerly known as Angiotech Pharmaceuticals, is a medical devices company engaged in the development, manufacturing and marketing of surgical instruments for its own brands. The company operates in the Europe, Asia-Pacific, Latin America and Canada. It is headquartered in Vancouver, Canada, and employed 1,364 people as of December 31, 2012. In August 2013, Angiotech Pharmaceuticals changed its name to Surgical Specialties Corporation. The company recorded revenues of $243.8 million during the financial year ended December 2012 (FY2012), an increase of 4.5% over FY2011. The operating profit of the company was $26.8 million in FY2012, as compared to an operating loss of $49.1 million in FY2011. The net loss was $6.2 million in FY2012, as compared to a net profit of $319.1 million in FY2011. Reasons to Purchase: - Gain understanding of Surgical Specialties Corporation, Inc. and the factors that influence its strategies - Track strategic initiatives of the company and latest corporate news and actions - Assess Surgical Specialties Corporation, Inc. as a prospective partner, vendor or supplier - Support sales activities by understanding your customers' businesses better - Stay up to date on Surgical Specialties Corporation, Inc.’s business structure, strategy and prospects

Why buy analyst research?

  • Institutional quality research
  • Available for Immediate Download
  • Detailed company or industry insight
  • Print or save
  • 24 hour customer support
Return to previous page without adding this item to your cart.
Email Customer Support.

About Analyst Research

Analyst research reports are available for immediate download after purchase. You will have unlimited access to the report for 24 hours after purchase, to download, print or save it as many times as you wish. Analyst Research provided by Reuters does not constitute investment advice, and is not endorsed by Reuters Research. This information is protected by copyright and intellectual property laws. More information on Analyst Research.